Alterations in erythrocyte fatty acid composition in preclinical Alzheimer's disease

Scientific Reports

Volumn 7, Issue 1, 2017, Pages

  Goozee, Kathryn ^{a,b,c,d,e,f,g}   Chatterjee, Pratishtha ^c,d,e   James, Ian ^h   Shen, Kaikai ^c,f,i   Sohrabi, Hamid R ^b,c,d,f,g   Asih, Prita R ^e,j   Dave, Preeti ^a   Ball, Bethany ^e   Manyan, Candice ^a   Taddei, Kevin ^c,f,g   Chung, Roger ^d   Garg, Manohar L ^k   Martins, Ralph N ^b,c,d,e,f,g  

^a Anglicare Sydney   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c EDITH COWAN UNIVERSITY   (Australia)

^d MACQUARIE UNIVERSITY   (Australia)

^e The KaRa Institute of Neurological Diseases   (Australia)

^f McCusker Alzheimer's Research foundation   (Australia)

^g University of Melbourne   (Australia)

^h MURDOCH UNIVERSITY   (Australia)

ⁱ CSIRO   (Australia)

^j UNIVERSITY OF NEW SOUTH WALES   (Australia)

^k UNIVERSITY OF NEWCASTLE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN E4; BIOLOGICAL MARKER; FATTY ACID; PROTEIN AGGREGATE;

AGED; ALZHEIMER DISEASE; BRAIN; ERYTHROCYTE; FAT INTAKE; FEMALE; GENETICS; HIPPOCAMPUS; HUMAN; LIPID METABOLISM; MALE; METABOLISM; PATHOLOGY; PROTEINOSIS; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; APOLIPOPROTEIN E4; BIOMARKERS; BRAIN; DIETARY FATS; ERYTHROCYTES; FATTY ACIDS; FEMALE; HIPPOCAMPUS; HUMANS; LIPID METABOLISM; MALE; PROTEIN AGGREGATES; PROTEIN AGGREGATION, PATHOLOGICAL; RISK FACTORS; ROC CURVE;

EID: 85018408487     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-017-00751-2     Document Type: Article

References (43)

1. Chan, R. B. et al. Comparative lipidomic analysis of mouse and human brain with Alzheimer disease. J Biol Chem 287, 2678-2688, doi:10.1074/jbc.M111.274142 (2012).
2. Nitsch, R. M. et al. Evidence for a membrane defect in Alzheimer disease brain. Proc Natl Acad Sci USA 89, 1671-1675, doi:10.1073/pnas.89.5.1671 (1992).
3. Soderberg, M., Edlund, C., Kristensson, K. & Dallner, G. Fatty acid composition of brain phospholipids in aging and in Alzheimers disease. Lipids 26, 421-425, doi:10.1007/BF02536067 (1991).
4. Cunnane, S. C. et al. Plasma and brain Fatty Acid profiles in mild cognitive impairment and Alzheimers disease. J Alzheimers Dis 29, 691-697, doi:10.3233/JAD-2012-110629 (2012).
5. Mapstone, M. et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat Med 20, 415-418, doi:10.1038/nm.3466 (2014).
6. Conquer, J. A., Tierney, M. C., Zecevic, J., Bettger, W. J. & Fisher, R. H. Fatty acid analysis of blood plasma of patients with Alzheimers disease, other types of dementia, and cognitive impairment. Lipids 35, 1305-1312, doi:10.1007/s11745-000-0646-3 (2000).
7. Kalmijn, S. et al. Dietary intake of fatty acids and fish in relation to cognitive performance at middle age. Neurology 62, 275-280, doi:10.1212/01.WNL.0000103860.75218.A5 (2004).
8. Morris, M. C. et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60, 940-946, doi:10.1001/archneur.60.7.940 (2003).
9. van Gelder, B. M., Tijhuis, M., Kalmijn, S. & Kromhout, D. Fish consumption, n-3 fatty acids, and subsequent 5-y cognitive decline in elderly men: The Zutphen Elderly Study. Am J Clin Nutr 85, 1142-1147 (2007).
10. Samieri, C. et al. Low plasma eicosapentaenoic acid and depressive symptomatology are independent predictors of dementia risk. Am J Clin Nutr 88, 714-721 (2008).
11. Schaefer, E. J. et al. Plasma phosphatidylcholine docosahexaenoic acid content and risk of dementia and Alzheimer disease: The Framingham Heart Study. Arch Neurol 63, 1545-1550, doi:10.1001/archneur.63.11.1545 (2006).
12. Esposito, G. et al. Imaging neuroinflammation in Alzheimers disease with radiolabeled arachidonic acid and PET. Journal of nuclear medicine: official publication, Society of Nuclear Medicine 49, 1414-1421, doi:10.2967/jnumed.107.049619 (2008).
13. Amtul, Z., Uhrig, M., Wang, L., Rozmahel, R. F. & Beyreuther, K. Detrimental effects of arachidonic acid and its metabolites in cellular and mouse models of Alzheimers disease: structural insight. Neurobiol Aging 33, 831 e821-831, doi:10.1016/j. neurobiolaging.2011.07.014 (2012).
14. Rao, J. S., Rapoport, S. I. & Kim, H. W. Altered neuroinflammatory, arachidonic acid cascade and synaptic markers in postmortem Alzheimers disease brain. Translational psychiatry 1, e31, doi:10.1038/tp.2011.27 (2011).
15. Chatterjee, P. et al. Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study. J Alzheimers Dis 50, 887-94, doi:10.3233/JAD-150948 (2016).
16. Villemagne, V. L. et al. Amyloid beta deposition, neurodegeneration, and cognitive decline in sporadic Alzheimers disease: A prospective cohort study. Lancet Neurol 12, 357-367, doi:10.1016/S1474-4422(13)70044-9 (2013).
17. Sanchez-Mejia, R. O. et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimers disease. Nat Neurosci 11, 1311-1318, doi:10.1038/nn.2213 (2008).
18. King, M. E., Gamblin, T. C., Kuret, J. & Binder, L. I. Differential assembly of human tau isoforms in the presence of arachidonic acid. J Neurochem 74, 1749-1757, doi:10.1046/j.1471-4159.2000.0741749.x (2000).
19. Wilson, D. M. & Binder, L. I. Free fatty acids stimulate the polymerization of tau and amyloid beta peptides. In vitro evidence for a common effector of pathogenesis in Alzheimers disease. Am J Pathol 150, 2181-2195 (1997).
20. Lipton, P. Ischemic cell death in brain neurons. Physiol Rev 79, 1431-1568 (1999).
21. Bazinet, R. P. & Laye, S. Polyunsaturated fatty acids and their metabolites in brain function and disease. Nature reviews. Neuroscience 15, 771-785, doi:10.1038/nrn3820 (2014).
22. Assies, J. et al. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biol Psychiatry 49, 510-522, doi:10.1016/S0006-3223(00)00986-0 (2001).
23. Kelly, L. et al. The polyunsaturated fatty acids, EPA and DPA exert a protective effect in the hippocampus of the aged rat. Neurobiol Aging 32, 2318 e2311-2315, doi:10.1016/j.neurobiolaging.2010.04.001 (2011).
24. Yassine, H. N. et al. Association of Serum Docosahexaenoic Acid With Cerebral Amyloidosis. JAMA neurology 73, 1208-1216, doi:10.1001/jamaneurol.2016.1924 (2016).
25. Heude, B., Ducimetiere, P., Berr, C. & Study, E. V. A. Cognitive decline and fatty acid composition of erythrocyte membranes-The EVA Study. Am J Clin Nutr 77, 803-808 (2003).
26. Gonzalez-Dominguez, R., Garcia-Barrera, T. & Gomez-Ariza, J. L. Metabolite profiling for the identification of altered metabolic pathways in Alzheimers disease. Journal of pharmaceutical and biomedical analysis 107, 75-81, doi:10.1016/j.jpba.2014.10.010 (2015).
27. Tan, Z. S. et al. Red blood cell omega-3 fatty acid levels and markers of accelerated brain aging. Neurology 78, 658-664, doi:10.1212/WNL.0b013e318249f6a9 (2012).
28. Pottala, J. V. et al. Higher RBC EPA + DHA corresponds with larger total brain and hippocampal volumes: WHIMS-MRI study. Neurology 82, 435-442, doi:10.1212/WNL.0000000000000080 (2014).
29. Chouinard-Watkins, R. & Plourde, M. Fatty acid metabolism in carriers of apolipoprotein E epsilon 4 allele: is it contributing to higher risk of cognitive decline and coronary heart disease? Nutrients 6, 4452-4471, doi:10.3390/nu6104452 (2014).
30. Minihane, A. M. et al. ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype. Arteriosclerosis, thrombosis, and vascular biology 20, 1990-1997, doi:10.1161/01.ATV.20.8.1990 (2000).
31. Whalley, L. J. et al. n-3 Fatty acid erythrocyte membrane content, APOE varepsilon4, and cognitive variation: An observational follow-up study in late adulthood. Am J Clin Nutr 87, 449-454 (2008).
32. Huang, T. L. et al. Benefits of fatty fish on dementia risk are stronger for those without APOE epsilon4. Neurology 65, 1409-1414, doi:10.1212/01.wnl.0000183148.34197.2e (2005).
33. Barberger-Gateau, P. et al. Dietary patterns and risk of dementia: The Three-City cohort study. Neurology 69, 1921-1930, doi:10.1212/01.wnl.0000278116.37320.52 (2007).
34. Schaeffer, E. L., Forlenza, O. V. & Gattaz, W. F. Phospholipase A2 activation as a therapeutic approach for cognitive enhancement in early-stage Alzheimer disease. Psychopharmacology 202, 37-51, doi:10.1007/s00213-008-1351-0 (2009).
35. Sun, G. Y. et al. Phospholipases A2 and inflammatory responses in the central nervous system. Neuromolecular medicine 12, 133-148, doi:10.1007/s12017-009-8092-z (2010).
36. Ellis, K. A. et al. The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimers disease. Int Psychogeriatr 21, 672-687, doi:10.1017/S1041610209009405 (2009).
37. Hixson, J. E. & Vernier, D. T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31, 545-548 (1990).
38. Lepage, G. & Roy, C. C. Direct transesterification of all classes of lipids in a one-step reaction. J Lipid Res 27, 114-120 (1986).
39. Ireland, P. et al. Development of the Melbourne FFQ: A food frequency questionnaire for use in an Australian prospective study involving an ethnically diverse cohort. Asia Pacific journal of clinical nutrition 3, 19-31 (1994).
40. Folstein, M. F., Folstein, S. E. & McHugh, P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198 (1975).
41. Crook, T. H. 3rd, Feher, E. P. & Larrabee, G. J. Assessment of memory complaint in age-Associated memory impairment: The MAC-Q. Int Psychogeriatr 4, 165-176, doi:10.1017/S1041610292000991 (1992).
42. Zhou, L. et al. MR-less surface-based amyloid assessment based on 11C PiB PET. PLoS One 9, e84777, doi:10.1371/journal. pone.0084777 (2014).
43. Bourgeat, P. et al. Comparison of MR-less PiB SUVR quantification methods. Neurobiol Aging 36(Suppl 1), S159-166, doi:10.1016/j. neurobiolaging.2014.04.033 (2015).